Concluding from this research, radiolabeled anti-id VHHs generate strong therapeutic efficacy against multiple myeloma in the MRD stage, which suggests that radiolabeled anti-id VHHs are valuable therapeutic agents to prevent cancer relapse in multiple myeloma patients. The gene discussed is ID1; the disease is plasma cell myeloma.